Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Arcus Biosciences, Inc.

Market Cap 3.06B 2.66B 2.46B 2.31B 4.32B 288B 4.35B 29.22B 11.35B 142B 11.48B 11.23B 492B P/E 2026 *
-6.62x
P/E 2027 * -7.21x
Enterprise Value 2.44B 2.12B 1.96B 1.84B 3.44B 230B 3.47B 23.28B 9.04B 113B 9.14B 8.95B 392B EV / Sales 2026 *
28.6x
EV / Sales 2027 * 30.1x
Free-Float
70.86%
Yield 2026 *
-
Yield 2027 * -
1 day+0.79%
1 week+9.90%
Current month-4.06%
1 month+2.23%
3 months+7.61%
6 months+9.11%
Current year+2.01%
1 week 23.27
Extreme 23.27
24.84
1 month 21.84
Extreme 21.84
26.15
Current year 18.52
Extreme 18.515
28.72
1 year 7.91
Extreme 7.91
28.72
3 years 6.5
Extreme 6.5
28.72
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 30/04/2015
Chief Executive Officer 67 30/04/2015
Director of Finance/CFO 53 31/07/2020
Director TitleAgeSince
Chairman 67 30/11/2017
Director/Board Member 65 17/09/2017
Director/Board Member 71 30/04/2015
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Director

22,600 0.0180%
06-10Free

Director

22,600 0.0180%
06-10Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
+0.79%+9.90%+179.43%+24.41% 3.03B
-0.34%-1.48%-12.18%-13.39% 43.44B
+3.31%+13.04%+316.43%+562.02% 33.54B
-1.70%-7.90%+8.87%-22.34% 28.48B
+2.84%+2.48%+6.32%+34.93% 29.2B
-0.57%+3.77%+12.66%+20.42% 25.34B
-0.14%+10.03% - - 14.36B
+0.68%-1.19%+54.47%+107.47% 13.05B
+0.54%-3.88%+3.69%+2.24% 12.67B
-0.26%+1.09%+105.03%+80.69% 12.28B
Average +0.52%+1.63%+74.97%+88.50% 21.54B
Weighted average by Cap. +0.60%+0.91%+66.82%+107.77%

Financials

2026 *2027 *
Net sales 85.06M 74.11M 68.32M 64.26M 120M 8.02B 121M 813M 316M 3.95B 319M 312M 13.69B 93.06M 81.08M 74.74M 70.3M 132M 8.77B 132M 889M 345M 4.32B 349M 342M 14.98B
Net income -456M -398M -367M -345M -645M -43.01B -650M -4.36B -1.69B -21.2B -1.71B -1.68B -73.47B -431M -375M -346M -325M -608M -40.58B -613M -4.11B -1.6B -20B -1.62B -1.58B -69.31B
Net Debt -621M -541M -499M -469M -878M -58.56B -884M -5.94B -2.31B -28.86B -2.33B -2.28B -100B -259M -226M -208M -196M -367M -24.44B -369M -2.48B -962M -12.05B -973M -953M -41.75B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
18/06/26 24.31 $ +0.79% 2,286,298
17/06/26 24.12 $ +2.42% 920,379
16/06/26 23.55 $ -2.61% 694,994
15/06/26 24.18 $ +1.60% 1,218,655
12/06/26 23.80 $ +2.15% 1,447,473
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
24.31USD
Average target price
35.75USD
Spread / Average Target
+47.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!